Home > Blog > Bi-Weekly Newsletter: 10.16.2020

Bi-Weekly Newsletter: 10.16.2020


How to Design a Good Phenotype Based Drug Discovery Program, and Why it Matters

With the advent of the molecular biology revolution and the human genome project in the 1990s  there was a historic shift toward target-based drug development. Yet a finding by Swinney and Anthony in 2011 resulted in a pendulum swing back towards phenotypic drug discovery. So what is the difference between the two, and how should you design your program in order for it to be successful?

Learn more

Featured Findings:

90 Mutations with 1 Gene: Functional Analysis of Variants Using C. elegans

We created over 90 point mutations in the STXBP1 gene via CRISPR! A map of these point mutations can be seen below. Clinical variants were selected from the ClinVar database, literature, the Gnomad database, clinical researchers, and the STXBP1 foundation.

Learn more


17 Minutes of Science: Biotechnology in the Time of Covid with Dr. Jeremy Levin

For episode 26 of 17 Minutes of Science, we are joined by Dr. Jeremy Levin. Dr Levin is the current chairman and CEO of Ovid Therapeutics, Inc. and the chairman of the Biotechnology Innovation Organization (BIO). Dr. Levin joins us to discuss his recent book and to dig a bit deeper into the impact of the current coronavirus pandemic on biotech, biopharma, and clinical trials.

Watch the recording


Understanding GPCRs Using Humanized C. elegans

Our CSO, Dr. Chris Hopkins recently attended the 1st DR. GPCR Summit and presented his talk titled ‘Understanding GPCRs Using Humanized C. elegans’. In his talk, he discussed the relevance of using C. elegans as a model organism to study GPCRs and why C. elegans is an ideal model to understand the underlying principles.

Watch his presentation


New Lifespan data

Our Longevity Platform offers researchers a streamlined way  to determine whether a compound can extend lifespan, promote a longer healthspan, and test the outcome on signaling pathways and cellular mechanisms promoting longer life. We recently updated our page to include new data and figures, check it out!

Learn more

Industry News:


Many of our 17 Minutes of Science conversations have touched on the subject of PhDs moving away from academia and how little support they felt during that process. This coming week we are very excited to have Dr. Jennifer Polk (a career coach specializing in life after PhD) joins us to discuss alternative careers for PhDs outside of academia, and provide support and insights to those considering transitioning away from academia.  RSVP here

Sign up so you never miss a newsletter

About The Author

InVivo Biosystems

InVivo Biosystems provides essential services to help pharmaceutical, nutraceutical, biotechnology companies and academic research institutions around the globe accelerate their research and drug development efforts. An expert in CRISPR genome editing, InVivo Biosystems creates custom genome edited C. elegans and zebrafish models to enable aging and other disease studies. In addition, InVivo Biosystems provides in-vivo analytical services to produce data and insights for companies that need to make go/no-go decisions quickly in early-stage development of new compounds.

Share this articles

InVivo Biosystems

About the Author:

Connect with us

Table of Contents